OBJECTIVE:: To apply the RE-AIM framework to examine factors that may have influenced the impact of a financial incentive smoking cessation intervention delivered at General Electric (GE) worksites. METHODS:: Intervention reach and efficacy were examined alone and in combination across worksites. Telephone interviews were conducted with worksite staff to explore organizational-level factors that may have influenced program adoption, implementation, and maintenance. Focus groups were conducted with employees to explore barriers and facilitators to program participation. RESULTS:: Intervention impact varied considerably across GE business industries when reach and efficacy both were examined instead of efficacy alone. Barriers that may have hindered program success include time constraints, competing priorities, work stress, and the lack of public visibility. CONCLUSION:: Employers considering financial incentive interventions for smoking cessation should examine how organizational context and real-world constraints may influence differential impact across sites
Application of the RE-AIM framework to evaluate the impact of a worksite-based financial incentive intervention for smoking cessation
Kim, A., Towers, A., Renaud, J., Zhu, J., Shea, J. A., Galvin, R., & Volpp, K. G. (2012). Application of the RE-AIM framework to evaluate the impact of a worksite-based financial incentive intervention for smoking cessation. Journal of Occupational and Environmental Medicine, 54(5), 610-614. https://doi.org/10.1097/JOM.0b013e31824b2171
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome